Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An
                    Overview

Niki Katsiki; Paschalis Steiropoulos; Nikolaos Papanas; Dimitri P. Mikhailidis

doi:10.1055/a-1038-3883

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2021; 129(10): 699-704
DOI: 10.1055/a-1038-3883

Review

Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview

Niki Katsiki

¹First Department of Internal Medicine, Diabetes Centre, Division of Endocrinology and Metabolism, AHEPA University Hospital, Thessaloniki, Greece

,

Paschalis Steiropoulos

²Department of Pneumonology, Democritus University of Thrace School of Health Sciences, Alexandroupolis, Greece

,

Nikolaos Papanas

³Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece

,

Dimitri P. Mikhailidis

⁴Department of Clinical Biochemistry, University College London, Royal Free Hospital Campus, London, United Kingdom of Great Britain and Northern Ireland

› Author Affiliations

Abstract

Chronic obstructive pulmonary disease (COPD) is a common disease with an increasing prevalence, characterised by persistent respiratory symptoms and airflow limitation. Apart from cigarette smoking, certain occupational and environmental exposures, low socioeconomic status and genetic factors may contribute to the pathogenesis of COPD. Comorbidities, e. g. diabetes mellitus (DM), can negatively affect quality of life, COPD outcomes and cardiovascular risk. The present narrative review considers the potential links between COPD and DM, such as systemic inflammation, oxidative stress, hypoxaemia and hyperglycaemia. The effects of antidiabetic drugs on lung function and COPD outcomes, as well as the possibility of common therapeutic modalities are also briefly considered. Further research is needed in this field to elucidate these relationships as well as their potential clinical implications in daily practice.

Key words

chronic obstructive pulmonary disease - obesity - type 2 diabetes mellitus

Full Text

References

References
1 GOLD Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2019;
2 Lozano R, Naghavi M, Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128
3 Adeloye D, Chua S, Lee C. et al Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Global Health 2015; 5: 020415
4 Lopez AD, Shibuya K, Rao C. et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006; 27: 397-412
5 Lytras T, Kogevinas M, Kromhout H. et al. Occupational exposures and 20-year incidence of COPD: The European Community Respiratory Health Survey. Thorax 2018; 73: 1008-1015
6 Doiron D, de Hoogh K, Probst-Hensch N. et al. Air pollution, lung function and COPD: Results from the population-based UK Biobank study. Eur Respir J 2019; 54(1): pii: 1802140
7 Wang M, Aaron CP, Madrigano J. et al. Association between long-term exposure to ambient air pollution and change in quantitatively assessed emphysema and lung function. JAMA 2019; 322: 546-556
8 Celli BR, Decramer M, Wedzicha JA. et al ATS/ERS Task Force for COPD Research An official American Thoracic Society/European Respiratory Society statement: Research questions in COPD. Eur Respir Rev 2015; 24: 159-172
9 May SM, Li JT. Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond. Allergy Asthma Proc 2015; 36: 4-10
10 Wacker ME, Jörres RA, Schulz H. et al. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respiratory Medicine 2016; 111: 39-46
11 Cavaillès A, Brinchault-Rabin G, Dixmier A. et al. Comorbidities of COPD. Eur Respir Rev 2013; 22: 454-475
12 Franssen FM, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: Do they matter?. Eur Respir Rev 2014; 23: 131-141
13 Mannino DM, Thorn D, Swensen A. et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969
14 Rogliani P, Lucà G, Lauro D. Chronic obstructive pulmonary disease and diabetes. COPD Research and Practice 2015; 1: 3
15 Lin CS, Liu CC, Yeh CC. et al. Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: Two nationwide population-based retrospective cohort studies. PLoS One 2017; 12: e0181815
16 van der Molen T. Co-morbidities of COPD in primary care: Frequency, relation to COPD, and treatment consequences. Prim Care Respir J 2010; 19: 326-334
17 Rana J, Mittleman MA, Sheikh J. et al. Chronic obstructive pulmonary disease, asthma and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 2478-2484
18 Lee CT, Mao IC, Lin CH. et al. Chronic obstructive pulmonary disease: a risk factor for type 2 diabetes: A nationwide population-based study. Eur J Clin Invest 2013; 43: 1113-1119
19 Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: A bitter sweet symphony. Cardiovasc Diabetol 2012; 11: 132
20 Rasmussen SM, Brok J, Backer V. et al. Association between chronic obstructive pulmonary disease and type 2 diabetes: A systematic review and meta-analysis. COPD 2018; 15: 526-535
21 Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010; 65: 930-936
22 Tiengo A, Fadini GP, Avogaro A. The metabolic syndrome, diabetes and lung dysfunction. Diabetes Metab 2008; 34: 447-454
23 Burt MG, Roberts GW, Aguilar-Loza NR. et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011; 96: 1789-1796
24 Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006
25 Herth FJ, Bramlage P, Müller-Wieland D. Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease. Respiration 2015; 89: 66-75
26 Caughey GE, Preiss AK, Vitry AI. et al. Comorbid diabetes and COPD: Impact of corticosteroid use on diabetes complications. Diabetes Care 2013; 36: 3009-3014
27 Parappil A, Depczynski B, Collett P. et al. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 2010; 15: 918-922
28 Baker EH, Janaway CH, Philips BJ. et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284-289
29 Gläser S, Krüger S, Merkel M. et al. Chronic obstructive pulmonary disease and diabetes mellitus: A systematic review of the literature. Respiration 2015; 89: 253-264
30 Koskela HO, Salonen PH, Romppanen J. et al. A history of diabetes but not hyperglycaemia during exacerbation of obstructive lung disease has impact on long-term mortality: a prospective, observational cohort study. BMJ Open 2015; 5: e006794
31 Hsu IL, Lu CL, Li CC. et al. Population-based cohort study suggesting a significantly increased risk of developing chronic obstructive pulmonary disease in people with type 2 diabetes mellitus. Diabetes Res Clin Pract 2018; 138: 66-74
32 Walter RE, Beiser A, Givelber RJ. et al. Association between glycemic state and lung function: The Framingham Heart Study. Am J Respir Crit Care Med 2003; 167: 911-916
33 Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: Findings from the British Women’s Heart and Health Study. Diabetologia 2004; 47: 195-203
34 McKeever TM, Weston PJ, Hubbard R. et al. Lung function and glucose metabolism: An analysis of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2005; 101: 546-556
35 Lange P, Parner J, Sohr P. et al. Copenaghen City Heart Study: Longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults. Eur Respir J 2002; 20: 1406-1412
36 Yeh HC, Punjabi NM, Wang NY. et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2008; 31: 741-746
37 Mekov EV, Slavova YG, Genova MP. et al. Diabetes mellitus type 2 in hospitalized COPD patients: Impact on quality of life and lung function. Folia Med (Plovdiv) 2016; 58: 36-41
38 Chiu HT, Li TC, Li CI. et al. Visit-to-visit glycemic variability is a strong predictor of chronic obstructive pulmonary disease in patients with type 2 diabetes mellitus: Competing risk analysis using a national cohort from the Taiwan diabetes study. PLoS One 2017; 12: e0177184
39 Li CI, Li TC, Liu CS. et al. Extreme values of hemoglobin a1c are associated with increased risks of chronic obstructive pulmonary disease in patients with type 2 diabetes: A competing risk analysis in National Cohort of Taiwan diabetes study. Medicine (Baltimore) 2015; 94: e367
40 Klein OL, Krishnan JA, Glick S. et al. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabet Med 2010; 27: 977-987
41 Cazzola M, Rogliani P, Calzetta L. et al. Targeting mechanisms linking copd to type 2 diabetes mellitus. Trends Pharmacol Sci 2017; 38: 940-951
42 Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. Transl Res 2017; 184: 101-107
43 Bellou V, Belbasis L, Tzoulaki I. et al. Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses. PLoS One 2018; 13: e0194127
44 Meteran H, Backer V, Kyvik KO. et al. Comorbidity between chronic obstructive pulmonary disease and type 2 diabetes: A nation-wide cohort twin study. Respir Med 2015; 109: 1026-1030
45 Aurora RN, Punjabi NM. Obstructive sleep apnoea and type 2 diabetes mellitus: A bidirectional association. Lancet Respir Med 2013; 1: 329-338
46 Rayner LH, McGovern AP, Sherlock J. et al. Type 2 diabetes: A protective factor for COPD?. Prim Care Diabetes 2018; 12: 438-444
47 Vitry AI, Roughead EE, Preiss AK. et al. Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: A cohort study. PLoS One 2010; 5: e14024
48 Kim HJ, Lee JY, Jung HS. et al. The impact of insulin sensitisers on lung function in patients with chronic obstructive pulmonary disease and diabetes. Int J Tuberc Lung Dis 2010; 14: 362-367
49 Tseng CH. Metformin and risk of chronic obstructive pulmonary disease in diabetes patients. Diabetes Metab 2019; 45: 184-190
50 https://www.endocrine-abstracts.org/ea/0041/ea0041EP543 Last accessed 26 August 2019
51 Bishwakarma R, Zhang W, Lin YL. et al. Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus. Int J Chron Obstruct Pulmon Dis 2018; 13: 793-800
52 Ho TW, Huang CT, Tsai YJ. et al. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respir Res 2019; 20: 69
53 Hitchings AW, Archer JR, Srivastava SA. et al. Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. COPD 2015; 12: 126-131
54 Yen FS, Chen W, Wei JC. et al. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design. PLoS One 2018; 13: e0204859
55 Mendy A, Gopal R, Alcorn JF. et al. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology 2019; 24: 646-651
56 Sexton P, Metcalf P, Kolbe J. Respiratory effects of insulin sensitisation with metformin: A prospective observational study. COPD 2014; 11: 133-142
57 Simental-Mendia LE, Pirro M, Atkin SL. et al. Effect of metformin on plasma fibrinogen concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Curr Pharm Des 2018; 24: 1034-1040
58 Papazafiropoulou A, Papanas N, Pappas S. et al. Effects of oral hypoglycemic agents on platelet function. J Diabetes Complications 2015; 29: 846-851
59 Fimognari FL, Scarlata S, Conte ME. et al. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3: 89-96
60 Malerba M, Clini E, Malagola M. et al. Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. Expert Rev Hematol 2013; 6: 475-483
61 Lakshmi SP, Reddy AT, Reddy RC. Emerging pharmaceutical therapies for COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 2141-2156
62 Papanas N, Katsiki N, Hatzitolios AI. et al. Pioglitazone: A valuable component of combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 2011; 12: 1457-1461
63 Katsiki N, Mikhailidis DP. Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. J Diabetes Complications 2017; 31: 1-3
64 Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006; 533: 101-109
65 Nader MA. Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma. Int Immunopharmacol 2015; 29: 761-769
66 Tai H, Wang MY, Zhao YP. et al. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy. Medicine (Baltimore) 2016; 95: e4541
67 Chilton R, Wyatt J, Nandish S. et al. Cardiovascular comorbidities of type 2 diabetes mellitus: Defining the potential of glucagon like peptide-1-based therapies. Am J Med 2011; 124: S35-S53
68 Viby NE, Isidor MS, Buggeskov KB. et al. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology 2013; 154: 4503-4511
69 Huang J, Yi H, Zhao C. et al. Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients. Int J Chron Obstruct Pulmon Dis 2018; 13: 3191-3202
70 Oztay F, Sancar-Bas S, Gezginci-Oktayoglu S. et al. Exendin-4partly ameliorates hyperglycemia-mediated tissue damage in lungs of streptozotocin-induced diabetic mice. Peptides 2018; 99: 99-107
71 Gerards MC, Venema GE, Patberg KW. et al. Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease. Diabetes Obes Metab 2018; 20: 1306-1310
72 Yaribeygi H, Katsiki N, Butler AE. et al. Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. Drug Discov Today 2019; 24: 256-262
73 Yaribeygi H, Butler AE, Atkin SL. et al. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. J Cell Physiol 2018; 234: 223-230
74 Batzias K, Antonopoulos AS, Oikonomou E. et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: A systematic review and meta-analysis. J Diabetes Res 2018; 1232583
75 Katsiki N, Mikhailidis DP, Theodorakis MJ. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their role in cardiometabolic risk management. Curr Pharm Des 2017; 23: 1522-1532
76 Katsiki N, Athyros VG, Mikhailidis DP. Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: Multiple actions. Curr Med Res Opin 2016; 32: 1513-1514
77 Verberne LDM, Leemrijse CJ, Swinkels ICS. et al. Overweight in patients with chronic obstructive pulmonary disease needs more attention: A cross-sectional study in general practice. NPJ Prim Care Respir Med 2017; 27: 63
78 Zammit C, Liddicoat H, Moonsie I. et al. Obesity and respiratory diseases. Int J Gen Med 2010; 3: 335-343
79 Steuten LM, Creutzberg EC, Vrijhoef HJ. et al. COPD as a multicomponent disease: Inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J 2006; 15: 84-91
80 Luo Y, Zhou L, Li Y. et al. Fat-Free Mass index for evaluating the nutritional status and disease severity in COPD. Respir Care 2016; 61: 680-688
81 Vorrink SN, Kort HS, Troosters T. et al. Level of daily physical activity in individuals with COPD compared with healthy controls. Respir Res 2011; 12: 33
82 Watz H, Waschki B, Kirsten A. et al. The metabolic syndrome in patients with chronic bronchitis and COPD: Frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039-1046
83 Franssen FM, O'Donnell DE, Goossens GH. et al. Obesity and the lung: 5. Obesity and COPD. Thorax 2008; 63: 1110-1117
84 Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediators Inflamm 2010; 2010: 585989
85 McClean KM, Kee F, Young IS. et al. Obesity and the lung: 1. Epidemiology. Thorax 2008; 63: 649-654
86 Poulain M, Doucet M, Major GC. et al. The effect of obesity on chronic respiratory diseases: Pathophysiology and therapeutic strategies. CMAJ 2006; 174: 1293-1299
87 Guenette JA, Jensen D, O'Donnell DE. Respiratory function and the obesity paradox. Curr Opin Clin Nutr Metab Care 2010; 13: 618-624
88 Röhling M, Herder C, Roden M. et al. Effects of long-term exercise interventions on glycaemic control in type 1 and type 2 diabetes: a systematic review. Exp Clin Endocrinol Diabetes 2016; 124: 487-494
89 Katsiki N, Ntaios G, Vemmos K. Stroke, obesity and gender: A review of the literature. Maturitas 2011; 69: 239-243
90 Morse SA, Gulati R, Reisin E. The obesity paradox and cardiovascular disease. Curr Hypertens Rep 2010; 12: 120-126
91 Chittal P, Babu AS, Lavie CJ. Obesity paradox: Does fat alter outcomes in chronic obstructive pulmonary disease?. COPD 2015; 12: 14-18
92 Marti S, Muñoz X, Rios J. et al. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J 2006; 27: 689-696
93 Spelta F, FrattaPasini AM, Cazzoletti L. et al. Body weight and mortality in COPD: Focus on the obesity paradox. Eat Weight Disord 2018; 23: 15-22
94 Lainscak M, von Haehling S, Doehner W. et al. Body mass index and prognosis in patients hospitalised with acute exacerbation of chronic obstructive pulmonary disease. J Cachex Sarcopenia Muscle 2011; 2: 81-86
95 McGhan R, Radcliff T, Fish R. et al. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132: 1748-1755
96 Prescott E, Almdal T, Mikkelsen KL. et al. Prognostic value of weight change in chronic obstructive pulmonary disease: Results from the Copenhagen City Heart Study. Eur Respir J 2002; 20: 539-544
97 Guo Y, Zhang T, Wang Z. et al. Body mass index and mortality in chronic obstructive pulmonary disease: A dose-response meta-analysis. Medicine (Baltimore) 2016; 95: e4225
98 Petersmann A, Nauck M, Müller-Wieland D. et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2018; 126: 406-410